Navigation Links
ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507

PHILADELPHIA, June 15 /PRNewswire/ -- ERT (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will be showcasing its portfolio of products and services at Booth #507 at the 45th Annual DIA Meeting, 21-25 June 2009 in San Diego, CA.

ERT will be showcasing, for the first time since its successful Company rebranding exercise, its four new sub-brands of its industry-leading products and services, including ERT ePRO Solutions, ERT Cardiac Safety Solutions, ERT EDC Solutions, and ERT Clinical Research Consulting Group. ERT representatives will be at the ERT booth at the DIA Annual Meeting to discuss the Company's latest innovations, as well as the latest advancements within the industry.

ERT is also inviting delegates to attend a presentation from its partner, Healthcare Technology Systems (HTS) Inc., which will be held on Wednesday, June 24, 3.30pm-5.00pm. The presentation entitled "Addressing Suicidality in Clinical Trials" will be chaired by John H. Greist, MD of HTS Inc and will discuss FDA safety concerns and regulatory requirements regarding suicidality assessments and the Columbia Suicide Severity Rating Scale (C-SSRS) and Columbia Classification Algorithm of Suicide Assessment (C-CASA). Delegates will be able to learn about computer-automated suicidality assessment options, as well as learn about methods and techniques for follow-up with patients. For further information or to register for this presentation, please visit

The DIA Annual Meeting is the biopharmaceutical industry's largest global event, drawing over 5,000 industry professionals each year and over 450 exhibiting companies from all over the world. Additionally, DIA Annual features over 400 conference sessions including key speakers from key regulatory agencies, e.g. FDA and EMEA.

ERT is a leading provider of technology and services to the biopharmaceutical and medical device industries around the world. The four key areas of ERT products and services are all enabled by the Company's innovative technology platform -- EXPERT(TM). EXPERT(TM) is a robust, secure, and validated clinical-research workflow-processing system that powers centralized electronic data collection, data management, and information exchange.

For further information about ERT's clinical trial solutions please visit Booth # 507 at DIA 45th Annual Meeting. Alternatively, email, call +1 215 972 0420 or visit

For further press information, contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email


Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.) ( is a provider of technology and services to the global biopharmaceutical and medical device industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2009 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TechConnect World Conference Showcases Houston Leaders May 3-7, at the George R. Brown Convention Center
2. Eklin Medical Systems to Showcase RapidStudy(TM) CDx Digital Radiography Systems at CVC East
3. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
4. Siemens Showcases New Hearing Loss Solutions at AudiologyNOW! Conference
5. ERT to Showcase Its Clinical Trials Portfolio at DIAs 21st Euromeeting
6. DAZ Systems, Inc. Showcases Oracle Business Accelerator for Agile Product Lifecycle Management
7. Stereotaxis Showcases Advancements for Remote Magnetic Ablations
8. NexBio to Present at 2009 Biotech Showcase
9. VivoMetrics to Present at the 2009 Biotech Showcase
10. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
11. Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition
Post Your Comments:
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology:
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 companies ... dominated by a few companies, according to Kalorama Information. These ... 51% of the market share of the 6.1 billion-dollar ... The World Market for Molecular Diagnostic s .    ... market is still controlled by one company and only ...
(Date:11/18/2015)... November 18, 2015 --> ... a new market report titled  Gesture Recognition Market - ... 2015 - 2021. According to the report, the global gesture recognition ... anticipated to reach US$29.1 bn by 2021, at a ... North America dominated the global gesture ...
Breaking Biology News(10 mins):